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Human metapneumovirus (HMPV), a common respiratory virus, can cause severe disease in pre- and post-
hematopoietic cell transplantation (HCT) recipients. We conducted a retrospective cohort analysis in HCT
patients with HMPV (n ¼ 23) or respiratory syncytial virus (n ¼ 23) detected in bronchoalveolar lavage
samples by reverse transcription PCR between 2006 and 2011 to determine disease characteristics and factors
associated with outcome. Mortality rates at 100 days were 43% for both HMPV and respiratory syncytial virus
lower respiratory tract disease. Steroid therapy, oxygen requirement >2 L or mechanical ventilation, and bone
marrow as cell source were signiﬁcant risk factors for overall and virus-related mortality in multivariable
models, whereas the virus type was not. The presence of centrilobular/nodular radiographic inﬁltrates was
a possible protective factor for mechanical ventilation. Thus, HMPV lower respiratory tract disease is asso-
ciated with high mortality in HCT recipients. Earlier detection in combination with new antiviral therapy is
needed to reduce mortality among HCT recipients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION analyses on BALwere done clinically in real time starting in January 2006 for
Human metapneumovirus (HMPV) is a paramyxovirus
closely related to respiratory syncytial virus (RSV). HMPV
occurs with a seasonal pattern in the general population
every winter and spring. Both HMPV and RSV cause similar
symptoms in immunocompetent children and adults and are
impossible to distinguish on a clinical basis [1]. HMPV
infections can cause severe and even fatal disease in immu-
nocompromised patients [2,3], with crude reported
mortality rates from HMPV pneumonia ranging from 10% to
80% in different small cohort studies of cancer and/or
hematopoietic cell transplantation (HCT) patients [3-6]. To
date, however, no study has directly compared lower respi-
ratory tract disease (LRTD) associated with HMPV with that
of RSV in immunocompromised patients. Although the
treatment and outcome of RSV LRTD in HCT has been rela-
tively well studied and standardized [7,8], few data are
available on the impact of HMPV LRTD during the time
surrounding HCT. The purpose of this study was to charac-
terize the clinical and radiographic presentation, viral load,
and factors associated with outcome of HMPV pneumonia in
HCT candidates and recipients and compare results with RSV
pneumonia.
METHODS
Patients and Samples
We retrospectively reviewed medical charts of all pre- and post-HCT
recipients with HMPV or RSV RNA detected in bronchoalveolar lavage
(BAL) samples by real-time reverse transcription (RT)-PCR. Molecularedgments on page 1225.
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13.05.005HMPV and March 2007 for RSV. This study included patients undergoing
BAL with HMPV or RSV detected through February 1, 2011. The RSV cases are
a subset of a series reported earlier [9]. Sera and nasal-wash specimens that
had been collected 11 days before to 11 days after each BAL were retro-
spectively identiﬁed and, if not previously tested for these viruses, were
evaluated for the presence of HMPV and RSV by RT-PCR.
Research was approved by the Institutional Review Board at Fred
Hutchinson Cancer Research Center. Informed consent was signed by study
participants.Laboratory Method
In addition to RSV and HMPV RT-PCR, respiratory viral diagnosis
for multiple respiratory viruses was performed on BAL specimens from pre-
and post-HCT recipients according to institutional protocol. Direct ﬂuores-
cent antibody (DFA) testing for inﬂuenza A and B, parainﬂuenza 1-3,
adenovirus, and RSV as well as RSV shell vial cultures were performed
on BAL samples between 2006 and 2011 as described in a previously
published protocol [10]. HMPV DFA testing was performed on BAL speci-
mens from February 2008 through 2011. BAL samples were also assessed
for a broad range of bacterial, fungal, and viral pathogens using standard
culture and staining methods as well as the aspergillus galactomannan
assay [11,12].
RT-PCR was performed on BAL, nasal-wash, and sera specimens
according to a previously published protocol [13]. Brieﬂy, total nucleic acids
were obtained from 200 mL of each BAL or nasal-wash sample by adding
400 mL lysis buffer. After incubation for 10 minutes at 60C, 600 mL of iso-
propanol was added and the samples were centrifuged at 13,000  g for
15 minutes. The pellets were washed with 1 mL 70% ethanol and suspended
in 200 mL RNAse free water. One-step RT-PCR reaction mixtures (TaqMan
One-Step RT-PCR Master Mix, Applied Biosystems, Foster City, CA) were
prepared using primers and probes targeting HMPV A/B and an internal
control or RSV A/B and an internal control as previously published [13]. The
reactions were performed and analyzed in a 7000 Sequence Detection
System (Applied Biosystems) under the following conditions: 30 minutes at
48C and 10 minutes at 95C, followed by 40 cycles of 15 seconds at 95C
and 1 minute at 60C. Sera extractions were performed using the QIAamp
RNA Mini Kit (Valencia, CA) as previously reported and provided a sensi-
tivity of 200 copies/mL for a cut-off of 10 copies per reaction [14]. Cycle
threshold values were converted into viral loads (copies/mL) of each virus
using stored standard curves made of RNA transcripts.Transplantation.
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Statistical comparisons were performed using chi-square test or Fisher’s
exact test for categorical variables (as appropriate), and Wilcoxon rank sum
test was used for continuous variables. The probability of survival was
estimated by the Kaplan-Meier method. Univariate and multivariate logistic
regression models were used to estimate odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs) for hypoxemia. Univariate and multivariate Cox
regression models were used to evaluate hazard ratios (HRs) and 95% CIs for
death by day 100 and virus-related death at day 100. Hypoxemia and
mechanical ventilation occurring after diagnosis were analyzed as time-
dependent variables. All reported P values were 2-sided and considered
signiﬁcant if P < .05. Analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC).RESULTS
Patients
Between January 2006 and February 2011, 23 severely
immunocompromised pre- or post-HCT patients had HMPV
detected by RT-PCR from BAL specimens. Between March
2007 and February 2011, 23 separate patients were found to
have RSV LRTD. Both groups had similar demographicTable 1
Demographic and Clinical Variables of Patients with Positive RT-PCR for HMPV or
Demographics and Clinical Variables
Sex, male
Age, yr, median (IQR)
HSCT (type)
Autologous
Allogeneic
Pre-HSCT
Cell source
Bone marrow
Peripheral blood stem cell
Cord blood
No transplantation
Total body irradiation*
12 Gy
2 Gy
None
GVHDy
Time after HCT,* days, median (IQR)
Time after HCT >100 days*
Lymphocyte count under 300 cells/mL at time of BAL
CMV reactivation within 1 mo before BAL*
Steroids within 2 wks before BAL
Copathogenz
Oxygen at diagnosis (>2 L þ ventilation)
Radiologic variables{
Centrilobular/nodular
Ground glass
Tree-in-bud
Alveolar
Treatment variables
Treatment with ribavirin only
Treatment with ribavirin and IVIG/palivizumab
Treatment with IVIG only
Time to start of treatment from ﬁrst positive sample, days, median (IQR)
Time to start of treatment from ﬁrst positive BAL, days, median (IQR)
Outcomes
Hypoxemia
Mechanical ventilation
Death at 100 days
Death related to RSV or HMPV infection
IQR indicates interquartile ratio; CMV, cytomegalovirus; GVHD, graft-versus-host
Values are total number of incidences with percents in parentheses, unless otherw
* HCT recipients only.
y Allo HCT recipients only.
z Some patients hadmore than one pathogen identiﬁed in the BAL or in the blood
was always the predominant virus based on viral loads. Fungal infections were dete
were known and treated at the time of respiratory virus diagnosis.
x Fungal (3), S. aureus, enterococcus (3), E. coli, Klebsiella (2), rhinovirus (2), S. vir
k Pneumocystis jiroveci, fungal (9),Haemophilus, S. pneumonia, Stenotrophomonas,
in BAL (2), herpes simplex virus in BAL, enteroccocus sepsis, staphylococcus sepsis
{ Only 22 of 23 patients with HMPV LRTD and 22 of 23 patients with RSV LRTDcharacteristics and levels of immunosuppression (Table 1).
All patients infected with RSV (with the exception of one
who declined therapy) were treated with aerosolized riba-
virin and palivizumab according to our institutional
protocol; treatment for HMPV was nonstandardized and
differed by care provided, because no standardized institu-
tional treatment guidelines were available. Among the 23
patients with HMPV LRTD, four received ribavirin alone, ﬁve
received intravenous immunoglobulin alone, and six
received both. Time to treatment after ﬁrst positive respi-
ratory sample (including nasopharyngeal secretions or BAL)
was a median of 5 days (range, 1 to 46 days) for HMPV and 1
day (range, 0 to 4 days) for RSV (Wilcoxon rank; P ¼ .0005),
and time to treatment after ﬁrst positive BAL had a median
of 2 days (range, 13 to 7 days) for HMPV and 0 days
(range, 15 to 2 days) for RSV (Wilcoxon rank; P ¼ .009).
HMPV and RSV were generally detected between Dec-
ember and June. One RSV cluster occurred during the study
period, December 2007, in which BAL samples from sevenRSV from BAL Samples
RSV (n ¼ 23) HMPV (n ¼ 23) P
16 (70) 15 (65) .75
58 (46-67) 50 (32-63) .095
4 (17) 3 (13) .84
15 (66) 14 (61)
4 (17) 6 (26)
3 (13) 6 (26) .43
18 (78) 13 (57)
2 (9) 3 (13)
0 1 (4)
3 (16) 2 (12) .58
9 (47) 11 (65)
7 (37) 4 (24)
13 (81) 11 (79) 1
106 (17-271) 80 (20-361) .85
10 (53) 8 (47) .74
9 (39) 11 (48) .55
7 (37) 6 (35) .92
13 (57) 9 (39) .24
8 (35)x 13 (57)k .18
11 (48) 8 (35) .23
13 (59%) 8 (36%) .13
15 (68%) 13 (59%) .53
4 (18%) 4 (18%) 1
14 (64%) 15 (68%) .75
0 (0) 4 (17) NA
22 (96) 6 (26) NA
0 (0) 5 (22) NA
1 (1-1) 5 (2-7) .0005
0 (1-1) 2 (1-5) .009
16 (70%) 15 (65%) .75
10 (43%) 7 (30%) .36
10 (43%) 10 (43%) 1
8 (35%) 9 (39%) .76
disease; IVIG, intravenous immunoglobulin.
ise noted.
at presentation.When another respiratory virus was identiﬁed, RSV or HMPV
rmined by blood or BAL galactomannan, microbiology, or pathology andmost
idians sepsis, Klebsiella sepsis.
enterococcus, parainﬂuenza, inﬂuenza A, rhinovirus (3), coronavirus (3), CMV
, gram-negative rod sepsis, vancomycin-resistant enterococcal sepsis.
had axial tomography performed.
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identiﬁed in May 2007 that included four patients with
HMPV LRTD. Two additional cases of RSV LRTD occurred
during the study period in which BAL samples were not
prospectively tested by RT-PCR and no samples were avail-
able for retrospective testing. These two patients were not
included in this study. All patients with HMPV LRTD were
tested by RT-PCR.
Virologic Results
Because HMPV DFA was not available before February
2008, only 14 of 23 HMPV-positive BAL samples were tested
by DFA and RT-PCR, whereas 22 of 23 RSV-positive BAL
samples were tested with bothmethods. Compared with RT-
PCR, HMPV DFA had a sensitivity of 71% (10/14), whereas
RSV DFA had a sensitivity of 86% (19/22). The difference
between HMPV and RSV mean viral loads in the ﬁrst BAL
sample (6.43 Log10 copies/mL, interquartile ratio, 5.79 to
7.97; and 7.13 Log10 copies/mL interquartile ratio, 6.34 to
8.11, respectively) did not reach statistical signiﬁcance
(Wilcoxon rank; P ¼ .17).Figure 1. (A) RT-PCR results on nasal washes (X) sampled within 11 days before or a
HMPV LRTD, whereas all patients with RSV LRTD had at least one positive nasal wa
(B) RT-PCR results on sera (X) sampled within 11 days before or after the positive BA
whereas two patients with RSV LRTD had positive sera (RSV patients two and sevenHMPVwas detected by RT-PCR in nasal washes from 10 of
15 patients who had been sampled within 11 days before or
after the BAL. In comparison, RSV was identiﬁed in all 14
patients who had nasal-wash samples tested. HMPV LRTD
patients who tested negative by nasal wash had lower viral
loads in their BAL specimens compared with those who
tested positive in the nasal wash (Figure 1A). Sera were ob-
tained from 30 patients (13 infected with HMPV and 17
infected with RSV) within 11 days before or after BAL. In one
patient with HMPV LRTD (viral load of 8.19 Log10 copies/mL),
HMPV RNAwas detected in two serum samples taken 4 days
apart. We detected RSV RNA in two patients with RSV LRTD
(viral load of 8.56 and 7.99 Log10 copies/mL); in one of these
two patients, RSV was detected in four serum samples over
a 10-day period starting the day before BAL until 9 days after.
All three patients with viral RNA in the sera died of severe
respiratory disease (Figure 1B).
Radiologic Results
Radiologic features of all 46 patients supported the diag-
nosis of a viral LRTD. Twenty-two patients with RSV LRTDfter the positive BAL. Negative nasal washes were found in ﬁve patients with
sh. Negative nasal washes were found in patients with lower BAL viral load.
L. One patient with HMPV LRTD had two positive sera (HMPV patient three),
). All three patients with positive sera had a high BAL viral load and died.
Figure 2. Kaplan-Meier survival estimates for (A) RSV and HMPV LRTD and (B) RSV or HMPV LRTD according to steroid dose. (C) HMPV LRTD treated with ribavirin
and untreated.
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computed tomography imaging. Centrilobular, ground-glass,
tree-in-bud, and alveolar opacities were found in similar
proportions among HMPV- and RSV-infected patients. Cen-
trilobular nodules were associated with less mechanical
ventilation in a model that adjusted for virus type (adjusted
OR, .18; 95% CI, 0 to 1.8; P ¼ .027), whereas ground-glass
opacities tended to be associated with increased rates ofhypoxemia in patients with RSV or HMPV LRTD (adjusted OR,
3.00; 95% CI, .8 to 11; P ¼ .1).
Outcome
Patients with HMPV and RSV LRTD had similar rates of
hypoxemia andmechanical ventilation at anytime during the
episode (Table 1). Two patients with HMPV LRTD refused
mechanical ventilation and subsequently died. Mortality
C. Renaud et al. / Biol Blood Marrow Transplant 19 (2013) 1220e12261224rates by day 100 after diagnosis were identical between
patients with HMPV and RSV LRTD (43% versus 43%), and
deaths related to the actual viral infection were also similar
(39% versus 35%). The Kaplan-Meier survival estimate is
presented in Figure 2A. We detected a higher frequency of
copathogens in patients with HMPV compared with those
with RSV LRTD (57% versus 35%); however, the difference
was not statistically signiﬁcant (P ¼ .175).
Risk Factors for Overall Mortality
In univariate Cox regression analyses, there were no
statistically signiﬁcant differences in outcome between
HMPV and RSV LRTD. However, stem cell source, steroid
treatment, and oxygen use were associated with overall
mortality by day 100 in patients with RSV or HMPV LRTD
(Table 2). Steroid treatment was also associated with overall
mortality in a dose-dependent fashion (Table 2). Similar
results were obtained when only HMPV LRTD cases were
analyzed (data not shown). Kaplan-Meier survival estimates
for patients with HMPV or RSV LRTD according to steroid
dose are shown in Figure 2B. In several multivariable models
that adjusted for cell source, oxygen requirement, and
steroid use, the virus type (RSV versus HMPV) was not
a signiﬁcant factor for mortality. Steroids at the time of
diagnosis of LRTD (adjusted HR, 4.1 to 7.9), peripheral blood
stem cell or cord blood as cell source (adjusted HR, .15 to .21),
and oxygen requirement > 2 L or mechanical ventilation at
diagnosis (adjusted HR, 3.6 to 4.6) were signiﬁcant risk
factors in multivariable models. Hypoxemia that occurred
after the diagnosis of LRTD (modeled as time-dependent
variable) was also associated with death (adjusted HR, 5.9;
95% CI, 1.3 to 25.9; P ¼ .02). Models that included virus type
and ribavirin treatment for HMPV (early versus late versus
none), type of radiographic presentation, viral load, or lym-
phopenia did not yield statistically signiﬁcant differences in
outcomes between the two viruses nor an association amongTable 2
Factors Associated with Overall Mortality at Day 100 after Diagnosis among
46 Patients with RSV or HMPV LRTD (Univariate Analysis)
Variable Death by Day 100
HR (95% CI) P
Virus (HMPV versus RSV) 1.11 (.5-2.7) .82
HCT (allo versus auto) 5.16 (.7-39) .11
GVHD (allo only) .96 (.3-3.0) .95
Cell source (PBSC versus BM) .18 (.07-.47) <.001
Time after HCT (>100 days versus <day 100) 2.02 (.8-5.2) .15
Lymphocyte count at diagnosis
(<300 cells/mm3 versus <300 cells/mm3)
1.95 (.8-4.7) .14
CMV reactivation at diagnosis (HCT only) .57 (.2-1.6) .29
Copathogens (present versus absent) 1.41 (.6-3.4) .45
Centrilobular/nodular opacities
(present versus absent)
.48 (.2-1.3) .14
Ground-glass opacities (present versus absent) 1.22 (.5-3.3) .69
Tree-in-bud opacities (present versus absent) .50 (.1-2.2) .36
Alveolar opacities (present versus absent) 1.98 (.7-6.0) .23
Steroids (any versus none) 4.99 (1.8-14) .002
Steroids (<1 mg/kg versus none) 3.80 (1.2-12) .02
Steroids (1 mg/kg versus none) 7.12 (2.3-22) <.001
Viral load in BAL (above versus below
third quartile)
.79 (.3-2.4) .68
Oxygen requirement at diagnosis
(>2 L/mechanical ventilation
versus no/2 L)
3.56 (1.41-8.99) .007
Hypoxemia after diagnosis (time dependent) 6.31 (1.46-27.2) .0014
Mechanical ventilation after diagnosis
(time dependent)
10.7 (4.04-28.2) <.001
GVHD indicates graft-versus-host disease; PBSC, peripheral blood stem cell;
BM, bone marrow; CNV, cytomegalovirus.the HMPV cases alone (data not shown). When ribavirin use
was treated as time-dependent variable (to account for
possible treatment biases), no detectable beneﬁcial effect
was found (HR, .99; 95% CI, .3 to 2.8). The median time
between transplantation and diagnosis of HMPVwas 18 days
in the group treated with ribavirin and 124 days in the
untreated group (Table 3). Kaplan-Meier survival estimates
for patients with HMPV LRTD who received ribavirin and
those who did not are shown in Figure 2C.
Risk Factors for Virus-Related Death
Variables from Table 2 were also assessed as possible risk
factors for virus-related mortality. There was no difference
between the two viruses while steroid use, oxygen use >2 L
or mechanical ventilation, hypoxemia after diagnosis (time-
dependent variable), and cell source remained signiﬁcant
predictors of poor outcome (data not shown). Centrilobular/
nodular inﬁltrates also tended to be protective (adjusted OR,
.35; 95% CI, .01 to 1.2; P ¼ .08). Ribavirin treatment was not
protective. Late use of ribavirin tended to be associated with
poorer outcome (adjusted OR, 4.0; 95% CI, .9 to 17; P ¼ .06).
Risk Factors for Hypoxemia and Mechanical Ventilation
An analysis of candidate variables (Table 2) for an asso-
ciation with hypoxemia or mechanical ventilation showed
a trend toward more hypoxemia with ground-glass inﬁl-
trates (adjusted OR, 2.97; 95% CI, .8 to 11; P ¼ .1). Cen-
trilobular/nodular inﬁltrates were protective in a model that
adjusted for virus type (adjusted OR, .18; 95% CI, .0 to .8; P ¼
.027). Ribavirin use was associated with hypoxemia (data not
shown).
DISCUSSION
HMPV may cause upper or lower respiratory tract infec-
tions in severely immunocompromised HCT recipients both
before and after transplantation. Asymptomatic shedding of
HMPV from the upper respiratory tract was reported previ-
ously, indicating that not all infections with HMPV neces-
sarily result in severe LRTD [15-17]. Studies have shown that
27% to 41% of HMPV upper respiratory tract infection prog-
ress to LRTD, but the outcome of LRTD is poorly described
[18]. We compared recent cases of RSV and HMPV LRTD
based on RT-PCR results of BAL samples with evaluation ofTable 3
Characteristics of 23 Patients with HMPV LRTD, According to Ribavirin
Therapy
Characteristic Treated with
Ribavirin (n ¼ 10)
No Ribavirin
(n ¼ 13)
Underlying disease
Acute leukemia 4 (40%) 4 (31%)
HD/MM/NHL 3 (30%) 6 (46%)
CML 1 (10%) 0 (0%)
CLL 0 (0%) 3 (23%)
Other 2 (20%) 0 (0%)
Donor type
Matched related 1 (10%) 1 (8%)
Mismatched/unrelated 5 (50%) 7 (55%)
Autologous 1 (10%) 2 (15%)
Pretransplant 3 (30%) 3 (22%)
Acute GVHD* 3 (50%) 7 (88%)
Median days post-HCT* 18 124
Ventilated at diagnosis 3 (30%) 2 (15%)
HD indicates Hodgkin disease; MM, multiple myeloma; NHL, non-Hodgkin
lymphoma; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; GVHD, graft-versus-host disease.
* Allogeneic recipients only.
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presentation, and factors associated with poor outcome. Our
study found an overall similarly poor outcome of HMPV and
RSV pneumonia and identiﬁed use of steroids as an impor-
tant factor associated with outcome.
Given the virologic similarities of RSV and HMPV, it is not
surprising that clinical outcomes are similar between these
viruses. However, in this study nearly all cases of RSV
pneumonia were treated with ribavirin, whereas only one-
half of patients with HMPV pneumonia received treatment.
Comparison of outcomes between treated and untreated
patients with HMPV LRTD in this nonrandomized, retro-
spective review did not show any beneﬁt of the drug. This is
possibly related to the increased time to treatment observed
in patients with HMPV LRTD compared with RSV LRTD, the
potential for more aggressive therapy in sicker patients, and
the shorter time between transplantation and HMPV diag-
nosis in the treated group of patients with HMPV LRTD
compared with the untreated group. We adjusted for
possible confounders such as the degree of acute lung injury
(measured by the degree of oxygen requirement) and
analyzed ribavirin use as a time-dependent variable to
account for difference of the start time of the drug between
patients. Nevertheless, the nonrandomized nature of the
treatment remains a key limitation.
In vitro studies and animal models have shown the efﬁ-
cacy of ribavirin against HMPV [19,20]. However, no clinical
studies have been conducted to evaluate treatment of HMPV
LRTD in HCT. Initiation of treatment at the earlier stage of
upper respiratory tract infection for RSV infection has been
shown to improve the outcome and reduces the progression
to LRTD [7]. The only prospective randomized study in
immunocompromised patients showed a decline of RSV viral
load and progression to LRTD, but the study was ended
prematurely and statistical signiﬁcancewas not reached [21].
HMPV infection has similar rates of progression to LRTD and
similar mortality compared with RSV, suggesting preemptive
treatment at earlier stages might potentially be useful. New
antiviral drugs are needed for both RSV and HMPV, and
prospective studies are needed to examine whether
preemptive therapy at the upper respiratory tract infection
stage is effective in preventing progression to LRTD.
Although lymphopenia is a well-known risk factor for
progression to LRTD in viral infections, we were not able to
show an impact of lymphocyte counts on mortality [22,23].
However, we identiﬁed steroid treatment, stem cell source,
and need for oxygen or mechanical ventilation as signiﬁcant
predictors for death. Steroids were primarily administered
for nonpulmonary graft-versus-host disease treatment.
Identifying steroid treatment, particularly high-dose steroid
treatment, as a major risk factor for death might help target
patients for interventions, including rapid steroid taper or
antiviral treatments, in the future.
Viral pneumonia in HCT recipients typically presents with
small, poorly deﬁned centrilobular nodules, tree-in-bud
opacities, ground-glass opacities, and consolidation [24,25].
These patterns can be present in various amounts in viral
pneumonia, including HMPV and RSV [26,27]. Our study,
which represents the ﬁrst comparison of RSV and HMPV viral
pneumonia in HCT, documented similar radiologic features
for both infections. As previously reported, ground-glass
opacity and centrilobular nodules were very common in
RSV (68% and 59%, respectively) and HMPV LRTD (59% and
36%, respectively). Tree-in-bud inﬁltrates were less common
(18% for both viruses). A signiﬁcant proportion of patientsalso demonstrated alveolar consolidation (64% for RSV and
68% for HMPV), corresponding to more extensive damage on
histologic examination [28]. Our study correlated radio-
graphic appearance with outcome demonstrating trends for
better survival in patients with centrilobular nodules and
worse prognosis in patients with ground-glass inﬁltrates,
which represent a more diffused disease. In addition to
detection of viral RNA in serum, this information could be
useful in managing patients and identifying those who could
beneﬁt from therapy. Viral RNA was detected in the sera of
one patient with HMPV LRTD and two patients with RSV
LRTD; all three died of severe disease, a correlation previ-
ously suggested in an earlier study [14]. We speculate that
detection of viral RNA in serum samples could become
a useful tool to predict or stratify the likelihood of short-term
survival in patients with HMPV or RSV LRTD. Larger studies
are needed to address this question.
We conclude that HMPV LRTD is associated with high
mortality rates after HCT. Use of corticosteroids, stem cell
source, and oxygen requirement at baseline and thereafter
were associated with poor outcome. The association of poor
outcome with high steroid doses suggests a possible inter-
vention (ie, tapering steroid dose if clinically possible). This
should be studied prospectively. Although this is the largest
series of HMPV LRTD in HCT recipients, the effect of ribavirin
couldnot be conclusivelydeterminedbecauseof small sample
size and confounding effects that led to the use of the drug.
However, initial results did not suggest a major effect. Larger
studies are needed to examine the effects of current and
future treatment options optimally in a randomized fashion.
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